Niagen Bioscience, Inc. (NAGE) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Niagen Bioscience, Inc. (NAGE) stock forecast summary
Our AI scores Niagen Bioscience, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Niagen Bioscience, Inc. is a small-cap company with a market capitalization of $164M. It ranks number 11 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For NAGE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NAGE included.
NAGE price chart and AI forecast
How NAGE ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Niagen Bioscience, Inc. (NAGE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | NAGE | Rank |
|---|---|---|
| Market Cap | $164M | 11/28 |
| P/E Ratio | 14.78x | – |
| P/B Ratio | 1.97x | 5/13 |
| EPS | $0.14 | – |
| Book Value/Share | $1.05 | – |
| Revenue/Share | $1.55 | – |
Profitability & Margins
| Metric | NAGE | Rank |
|---|---|---|
| ROE | 12.3% | 2/15 |
| ROA | 9.4% | 2/21 |
| ROIC | 5.2% | 5/18 |
| Gross Margin | 63.9% | 5/21 |
| Operating Margin | 3.9% | 4/23 |
| Net Margin | 8.4% | 2/19 |
| EBT Margin | 9.0% | 3/23 |
| Tax Rate | 7.4% | – |
Financial Health
| Metric | NAGE | Rank |
|---|---|---|
| Current Ratio | 5.93x | 3/25 |
| Quick Ratio | 4.71x | 2/23 |
| D/E Ratio | 0.31x | 12/16 |
| Financial Leverage | 1.31x | 13/16 |
| Interest Coverage | 4086.0x | 1/21 |
| Working Capital | $83M | 8/25 |
Cash Flow
| Metric | NAGE | Rank |
|---|---|---|
| Operating Cash Flow | $5M | 10/27 |
| OCF Growth YoY | -77.2% | 8/10 |
Operational Efficiency
| Metric | NAGE | Rank |
|---|---|---|
| Asset Turnover | 1.13x | 5/15 |
| Receivables Turnover | 17.9x | 7/14 |
| Inventory Turnover | 2.1x | 16/19 |
| Fixed Assets Turnover | 100.6x | 3/16 |
| Days Sales Outstanding | 20 days | 8/14 |
| Days Inventory | 170 days | 3/18 |
| Payables Period | 95 days | 2/17 |
| Cash Conversion Cycle | 95 days | 8/12 |
Income Statement
| Metric | NAGE | Rank |
|---|---|---|
| Total Revenue | $122M | 12/17 |
| Operating Income | $5M | 4/26 |
| Net Income | $10M | 1/21 |
| R&D Expense | $6M | 4/8 |
| SG&A Expense | $41M | 8/16 |
| Cost of Goods Sold | $44M | 11/22 |
Dividend & Shareholder Information
| Metric | NAGE | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
| Net Income Growth | -49.9% | 2/5 |
| EPS Growth | 0.0% | 2/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $100M | 92.1% of assets |
| Cash & Short-term Investments | $70M | 63.9% of assets |
| Accounts Receivable | $7M | 6.3% of assets |
| Inventory | $21M | 18.9% of assets |
| Total Liabilities | $26M | 23.6% of assets |
| Short-term Debt | $5M | 5.0% of assets |
NAGE quarterly financials and insider trading
Niagen Bioscience, Inc. (NAGE) industry peers
Companies classified under the same SEC industry code as Niagen Bioscience, Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NAGE Niagen Bioscience, Inc. | $164M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where NAGE sits on the market map
Niagen Bioscience, Inc. (NAGE) stock news
📰 We are currently updating our news feed for Niagen Bioscience, Inc.. Check back soon for the latest market analysis and company updates.
Niagen Bioscience, Inc. (NAGE) stock forecast FAQ
What is the Niagen Bioscience, Inc. (NAGE) stock forecast?
Our AI scores Niagen Bioscience, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Niagen Bioscience, Inc. stock predictions?
For NAGE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 53.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Niagen Bioscience, Inc. forecasts updated?
Niagen Bioscience, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Niagen Bioscience, Inc.'s industry peers?
30 issuers in our coverage, NAGE included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.